Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
Stopped early · Phase 4 · Has a placebo group
Conditions studied: Mood, Memory Deficit
In brief
The primary purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given either memantine or riluzole pretreatment will show lesser declarative memory impairment than those receiving placebo. The exploratory purpose is to determine if patients scheduled to receive prescription corticosteroid therapy for inflammatory illnesses who are given memantine or riluzole pretreatment will show a smaller increase in manic/hypomanic symptom severity than those receiving placebo.
Key facts
- Study ID
- NCT00283309
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 20
- Starts
- 2005-11-01
- Expected to finish
- 2007-04-01
- Last updated by the study team
- 2013-04-23
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18-70 years old
- English speaking
- Able to provide informed consent
- Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days
You may not qualify if…
- History of allergic reaction to memantine and/or riluzole
- Pregnant or nursing women
- History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition
- Mental retardation, dementia, or other severe cognitive disorder
- Prior prednisone therapy in the last 14 days
- Current alcohol/substance abuse/dependence
Where it is running
- UT Southwestern — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.